par Wouters, A.;Durieux, Valérie
;Kolivras, Athanassios
;Meert, Anne-Pascale
;Sculier, Jean-Paul 
Référence Anticancer research, 39, 6, page (3003-3008)
Publication Publié, 2019-06-01




Référence Anticancer research, 39, 6, page (3003-3008)
Publication Publié, 2019-06-01
Article révisé par les pairs
Résumé : | Various immune-related adverse events (irAEs) have been reported to be associated with the use of immune checkpoint inhibitors. We report a case of a patient with lung cancer treated with nivolumab who developed a bullous eruption and give a systematic review of the literature on irAEs in patients treated with immune checkpoint inhibitors for lung cancer. |